MBPCre-9 MBPCre-9 RBRC01461 Cre/loxP system mouse MBP genomic DNA, Simian virus 40 Large T antigen nuclear localization signal (nls), phage P1 Cre recombinase gene, synthetic intron from pOG3231, rabbit beta-globin 3' splicing and polyadenylation signals B (1-3 months) Sibling Mating 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Genesis, 26, 127-129 (2000). <br>研究成果の公表にあたって謝辞の表明を必要とする。<br>RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. MBPCre-9 INSERM INSERM FVB/N-Tg(Mbp-cre)9Gvn. MbpCre contains a transcriptional unit consisting of a myelin specific promoter (myelin basic protein) and Cre recombinase gene. This strain can be used to make a inducible knock out by crossing with other conditional knock out mice that have floxed genes. This transgene is expressed in myelinating oligodenderocytes in the CNS, testis and pituitary gland. FVB/N-Tg(Mbp-cre)9Gvn/GvnRbrc <a href='https://brc.riken.jp/mus/pcr01461'>Genotyping protocol -PCR-</a> Developed by Drs. Michiko Niwa-Kawakita and Marco Giovannini at INSERM, France in 2000. MbpCre transgene fragment consisnting of Cre recomnbinase and mouse myelin protein promoter was injected into the pronuclei of FVB/N fertilized egges. Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> true Marco Giovannini Marco Giovannini In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Genesis, 26, 127-129 (2000). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. B（1〜3か月）